For the study, researchers tracked 1,070 kids aged 12 to 18 who were overweight or obese and also had a diagnosis of asthma.

SAVING’ jab for severe asthma that could prevent deadly attacks with just two doses a year could be available to patients in ...

Marketed as Exdensur, the ultra-long-acting biologic is the first of its kind, requiring only two injections per year to ...

The treatment, which will be sold under the brand name Exdensur, is an “ultra-long-acting” version of a biologic treatment ...

The FDA approved depemokimab (Exdensur) as the first ultra-long-acting biologic with twice-yearly dosing approved for patients with severe asthma with an eosinophilic phenotype, GSK announced.

Two replicate phase 3 trials of GB-0895, an anti-thymic stromal lymphopoietin antibody, are enrolling adults and adolescents ...

The Food and Drug Administration (FDA) has approved Exdensur (depemokimab-ulaa), an interleukin-5 antagonist, for add-on maintenance treatment of severe asthma characterized by an eosinophilic ...

Asthma remains one of the most prevalent chronic diseases in the US. 3 Although poor adherence substantially contributes to inadequate outcomes, even patients with high adherence often experience ...

The authors write that once severe asthma is diagnosed, clinicians should determine asthma endotype (Type2-high or Type2-low) to help choose the best therapy for the patient. Asthma endotype, clinical ...

An asthma treatment that only requires patients to have two jabs a year to prevent life-threatening attacks will be available ...

Although it is recognized that airway inflammation is key to asthma pathogenesis, the marked heterogeneity in its clinical course and variations in response to treatment make it a challenging ...

This year’s top asthma and respiratory disorder story focused on the pushback from multiple advocacy groups following ...